title: Acylated-based long-acting insulin analogues: is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes.
authors.forename: L
authors.initials: L
authors.lastname: Monnier
authors.forename: C
authors.initials: C
authors.lastname: Colette
authors.forename: D
authors.initials: D
authors.lastname: Owens
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives*
chemical_list: D007328:Insulin